Descrizione del progetto
Comprensione genetica della sclerosi multipla
La sclerosi multipla (SM) è una malattia autoimmune che colpisce la guaina mielinica degli assoni del sistema nervoso centrale. Gli studi sull’intero genoma hanno rivelato diverse variazioni genetiche correlate al rischio di SM, legate innanzitutto ai geni delle cellule immunitarie. Finanziato dal Consiglio europeo della ricerca, il progetto SingleMS si avvarrà dell’omica a singola cellula per studiare il ruolo attivo degli oligodendrociti, le cellule che producono mielina. L’attenzione si concentrerà sull’accessibilità alla cromatina e sull’espressione genica di queste variazioni genetiche correlate a questi polimorfismi/varianti a singolo nucleotide. La caratterizzazione del paesaggio trascrittomico ed epigenomico degli oligodendrociti umani fornirà importanti informazioni sulla patogenesi della SM, aprendo la strada a potenziali strategie terapeutiche.
Obiettivo
Multiple sclerosis (MS) is a neurological disease characterized by autoimmune attack targeting oligodendroglia (OLG) in the central nervous system (CNS), and in particular their myelin, which ensheaths neuronal axons. Genome-wide association studies (GWAS) have led to the identification of hundreds of single-nucleotide polymorphisms (SNPs) and variants that are associated with MS risk. Many of these are located near genes associated with immune cells, indicating a key role for these cells in MS. Using single-cell omics approaches, we recently found that OLG present chromatin accessibility or express genes associated with some of these SNPs/variants, both in health and disease. Here, we hypothesize that OLG have a more active role in MS than previously anticipated, and therefore we will determine the function of MS SNPs/variants in OLG in the context of MS, using humanized mouse models, patient samples and new single-cell omics techniques recently developed in my group. We will 1) characterize in-depth the transcriptomic and epigenomic landscape of human and mouse OLG in the context of MS, to identify putative genes affected by the SNPs/variants; 2) perform CRISPR-guided editing of a cohort of the identified SNPs/variants in human OLG, and determine the consequences of the editing at a) an epigenomic and transcriptional level, linking specific SNPs/variants to their bona-fide target genes, and b) a functional level, by performing an array of functional assays targeting myelination, cell survival, and immune function, both in vitro and in humanized mouse chimeras in which engineered human OLG have been transplanted. We will use single-cell and spatial omics technologies, such as nanoCUT&Tag and spatial CUT&Tag, among others which we have recently developed in my research group. The results of this project will yield unique insights into the role of OLG and the identified SNPs/variants in MS, and thereby pave the way to novel therapeutic avenues for this disease.
Campo scientifico
Parole chiave
Programma(i)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Argomento(i)
Meccanismo di finanziamento
HORIZON-ERC - HORIZON ERC GrantsIstituzione ospitante
17177 Stockholm
Svezia